Finoriq research workspace
Annovis Bio, Inc. (ANVS) News
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in. Review ANVS recent headlines, source links, and company news on Finoriq.
Company Snapshot
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
- Company
- Annovis Bio, Inc. (ANVS)
- Ticker
- ANVS
- Market Cap
- $59.1M
- Latest Price
- $1.705
- Industry
- Biotech & Pharma
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.